Following the excitement of its proposed acquisition of Loxo Oncology Inc. and its intensified strategic focus on cancer therapies, Lilly has been brought back to earth with a bang following the failure of already-approved Lartruvo (olaratumab) in a late-stage trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?